.webp)
Transforming Mental Health With Precision Targeted Neuromedicines
Second-generation DMT–harmala neuromedicines with proprietary chemistry and strong clinical validation
View Our PipelineThe Problem
Despite decades of advances, existing mental health treatments remain narrowly focused on symptoms, and too often fail to deliver meaningful or enduring relief.
Our Mission
Our mission is to develop precision-targeted neuromedicines that engage key biological and psychological pathways to deliver transformative treatments for mental illness.
Our Approach
Our proprietary DMT–harmala platform enables second-generation neuromedicines with differentiated multi-target pharmacology and short- and medium-duration formats.
Neuroplasticity and Neuromodulation
Emotional Processing and Self-Insight
Increased Psychological Resilience
Our Science
We combine precision formulation design with advanced pharmaceutical science to deliver scalable, transformative therapies.
Our Phase 1 data, published in Scientific Reports, demonstrated acute effects exceeding published psilocybin and LSD benchmarks, with favourable tolerability and persisting psychological benefits.
Learn MoreWorld Leading Expertise
Neurala’s founding team are global leaders in the development and clinical translation of DMT-harmala therapeutics, with dozens of published scientific papers on the therapeutic potential of these compounds.
Learn More
